Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer
Status:
Active, not recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
This study aims to improve locoregional control of poor prognosis Head and Neck Cancer (HNC)
patients by selectively escalating the radiotherapy dose to subvolumes of tumor likely to be
resistant to standard Radiation Therapy (RT) using DCE-MRI (Dynamic Contrast Enhanced
Magnetic Resonance Imaging). Standard doses of radiotherapy to the rest of the tissues and
surrounding normal tissues will be maintained.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center